Galidesivir
Galidesivir
Galidesivir (pronounced gah-lee-deh-see-veer) is an antiviral drug currently under investigation for its potential use in the treatment of various viral diseases. The drug was initially developed by BioCryst Pharmaceuticals, a company specializing in the development of small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Etymology
The name "Galidesivir" is a portmanteau of the words "Gali" and "desivir". The exact etymology is not known, but "desivir" is a common suffix in the names of antiviral drugs.
Mechanism of Action
Galidesivir is a broad-spectrum antiviral that works by inhibiting the RNA polymerase enzyme, which is essential for viral replication. By blocking this enzyme, Galidesivir prevents the virus from replicating within the host's cells.
Clinical Trials
Galidesivir has been tested in clinical trials for its efficacy against several viruses, including the Zika virus, Ebola virus, and the Marburg virus. It is also being investigated for potential use against the SARS-CoV-2 virus, which causes COVID-19.
Related Terms
- Antiviral drug
- RNA polymerase
- Viral replication
- Zika virus
- Ebola virus
- Marburg virus
- SARS-CoV-2
- COVID-19
External links
- Medical encyclopedia article on Galidesivir
- Wikipedia's article - Galidesivir
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski